Stock Quote (NASDAQ: ASMB)
Price:
6.77
Change:
- 0.32
Day High:
7.10
Day Low:
6.70
Volume:
30,900
3:59 PM ET on Aug 19, 2014
Delayed at least 20min., by eSignal.
Investor Relations

SHAREHOLDER TOOLS
Briefcase Printed Materials Email Alerts
Download Center snapshot RSS Mobile Investor

PROXY STATEMENT
2014 Proxy Statement
ANNUAL REPORT
2013 Annual Report
Stock price graph
     

Ventrus BioSciences, Inc. is a development-stage specialty pharmaceutical company currently focused on the development of gastrointestinal (GI) products, including infections of the GI system. Ventrus believes it has completed clinical development of VEN 307 and has scheduled a meeting with the FDA on June 19, 2014 to discuss the filing of an NDA. Ventrus also has an early-stage program in microbiome therapeutics, VEN 310, which it is developing as an oral colonic delivery mechanism for bacteria, complex proteins, viral antigens and small molecules.

View all »   RSSRecent Releases

Jul 14, 2014
Ventrus Biosciences Becomes Assembly Biosciences as Stockholders Approve Merger With Assembly Pharmaceuticals, Inc.

Jun 9, 2014
Ventrus Biosciences Files and Commences Mailing of Definitive Proxy Materials for July 10th Annual Meeting

 
Home About Ventrus Product Pipeline Contact Investor Relations